FINWIRES · TerminalLIVE
FINWIRES

摩根士丹利稱,高通手機業務成長仍面臨重大挑戰

By

-- 摩根士丹利週四在一份報告中指出,高通(QCOM)預計手機銷量將連續第二季低於季節性需求,原因是內存需求對中國安卓市場造成了衝擊。報告還補充說,隨著5G技術的不斷成熟,手機成長仍面臨巨大挑戰。 高通表示,根據專利費數據和客戶回饋,6月份可能是中國安卓市場的底部。然而,由於三星和蘋果(AAPL)的市佔率下滑,高通無法確定9月手機銷量是會上升還是下降,而摩根士丹利則預測9月環比成長將持平。 摩根士丹利指出,高通預計6月汽車業務年增50%,比摩根士丹利的預期高出約7%,這主要得益於週期性成長和在研產品數量的成長。該券商表示,儘管汽車業務佔總銷售額的不到15%,但其成長動能依然強勁。 報告還指出,高通目前正在尋求客製化晶片,但市場已被大型供應商佔據。該公司表示,需要更清楚地了解這些成功案例,但在這方面取得的進展至關重要。 摩根士丹利目前預測高通2026年的營收和每股盈餘分別為401億美元和9.39美元,2027年的營收和每股盈餘分別為420億美元和10.32美元。 摩根士丹利維持對高通的「減持」評級,同時將目標股價從132美元上調至146美元。 高通股價週四上漲近16%。

Price: $181.68, Change: $+25.68, Percent Change: +16.46%

Related Articles

Sectors

Sector Update: Financial

Financial stocks were higher late Thursday afternoon, with the NYSE Financial Index rising 1.3% and the State Street Financial Select Sector SPDR ETF (XLF) up 0.5%.The Philadelphia Housing Index climbed 1.6%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) added 1.5%.Bitcoin (BTC-USD) rose 0.9% to $76,409, and the yield for 10-year US Treasuries decreased 2.8 basis points to 4.39%.In corporate news, AvalonBay Communities (AVB) and Equity Residential (EQR) have held discussions over a potential merger, which would be one of the biggest real estate deals ever, Bloomberg reported. AvalonBay shares were down 1.1%, and Equity Residential was fractionally lower.

$AVB$EQR
Australia

Market Chatter: Zuckerberg, Cook Not Exploring Seattle Seahawks Bid

Meta Platforms (META) CEO Mark Zuckerberg and Apple (AAPL) CEO Tim Cook are not pursuing a bid for the National Football League's Seattle Seahawks, Bloomberg reported on Thursday, citing company and industry sources.A Meta spokesperson said Zuckerberg is not making any investment or bid for the team, while a person familiar with Cook's plans denied his involvement, the report said.Meta and Apple did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $616.43, Change: $-52.69, Percent Change: -7.87%

$AAPL$META
Australia

Axsome Therapeutics Says FDA Approves Auvelity for Alzheimer's Disease Agitation

Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%

$AXSM